NCT06890923View on ClinicalTrials.gov

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

August 30, 2026

Conditions
Non-Active Secondary Progressive Multiple Sclerosis
Interventions
DRUG

Foralumab TZLS-401 100 µg

Patients meeting the requirements of the dose escalation rules will receive nasal foralumab 100 µg three (3) days a week (Monday-Wednesday-Friday) for two weeks, followed by a one-week rest, comprising 3-week cycles.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Tiziana Life Sciences LTD

INDUSTRY